NCT07415031ClinicalTrials.gov
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
Kurz gefasst
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC)…
Phase 2170 Teilnehmende gesucht101 Studienzentren21 Länder
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT07415031Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert letzte Woche
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-02-17; recorded start 2026-05-06
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Mirati Therapeutics Inc.)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 100 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 170 participants (target), run at 101 sites, across 21 countries.
How this score is built
- Enrolment21/40
170 participants (target)
- Site count23/25
100 sites
- Country count15/15
20 countries
- Planned duration7/10
Planned over about 22 months
- Sponsor scale4/10
Mirati Therapeutics Inc. has led 19 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Erkrankungen
- Solid Tumors
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Phase 2 |
| Zuteilung | Nicht zutreffend |
| Interventionsmodell | PARALLEL |
| Primäres Ziel | TREATMENT |
| Verblindung | NONE (0) |
| Teilnahme | 170 Teilnehmende gesucht |
Sponsor und Mitwirkende
- Mirati Therapeutics Inc. Sponsor
Studienarme und Interventionen
- Arm A1EXPERIMENTAL
- Arm A2EXPERIMENTAL
- Arm B1EXPERIMENTAL
- Arm B2EXPERIMENTAL
- Arm B3EXPERIMENTAL
- Arm B4EXPERIMENTAL
- Arm C1EXPERIMENTAL
- Arm C2EXPERIMENTAL
- Arm C3EXPERIMENTAL
- Arm C4EXPERIMENTAL
Interventionen
- Arzneimittel Adagrasib
Specified dose on specified days
- Arzneimittel Cetuximab
Specified dose on specified days
- Arzneimittel Docetaxel
Specified dose on specified days
- Arzneimittel Fluorouracil
Specified dose on specified days
- Arzneimittel Irinotecan
Specified dose on specified days
- Arzneimittel Leucovorin
Specified dose on specified days
- Arzneimittel Oxaliplatin
Specified dose on specified days
- Arzneimittel Pembrolizumab
Specified dose on specified days
- Arzneimittel Pemetrexed
Specified dose on specified days
Endpunkte
Primärer Endpunkt
Number of Participants With Adverse Events (AEs)
Zeitrahmen Up to 90 days from last dose or study discontinuation
Primärer Endpunkt
Number of Participants With AEs Leading to Treatment Discontinuation
Zeitrahmen Up to 90 days from last dose or study discontinuation
Primärer Endpunkt
Number of Participants With Serious Adverse Events (SAEs)
Zeitrahmen Up to 90 days from last dose or study discontinuation
Primärer Endpunkt
Number of Participants With AEs Leading to Death
Zeitrahmen Up to 90 days from last dose or study discontinuation
Daten
| Startdatum | 6. Mai 2026 (tatsächlich) |
|---|---|
| Primärer Abschluss | 16. Februar 2028 (geschätzt) |
| Abschluss | 16. Februar 2028 (geschätzt) |
| Erstveröffentlichung | 17. Februar 2026 (tatsächlich) |
| Zuletzt aktualisiert | 12. November 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | November 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
81 Studienzentren rekrutieren
Australia
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Local Institution - 0093 | St Leonards | New South Wales | Zurückgezogen |
Belgium
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| AZ Maria Middelares | Ghent | Rekrutiert |
Brazil
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Clinical Oncology | São Paulo | Rekrutiert | |
| Fundacao Antonio Prudente - AC Camargo Cancer Center | São Paulo | Rekrutiert |
Canada
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| BC Cancer - Vancouver | Vancouver | British Columbia | Rekrutiert |
China
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Local Institution - 0037 | Beijing | Beijing Municipality | Zurückgezogen |
| Local Institution - 0038 | Changsha | Hunan | Zurückgezogen |
| Local Institution - 0040 | Chengdu | Sichuan | Zurückgezogen |
| Local Institution - 0044 | Hangzhou | Zhejiang | Zurückgezogen |
| Local Institution - 0039 | Jinan | Shandong | Zurückgezogen |
| Local Institution - 0047 | Linyi | Shandong | Zurückgezogen |
| Local Institution - 0048 | Nanchang | Jiangxi | Zurückgezogen |
| Local Institution - 0046 | Nanjing | Jiangsu | Zurückgezogen |
| Local Institution - 0043 | Shanghai | Shanghai Municipality | Zurückgezogen |
| Local Institution - 0049 | Shenyang | Liaoning | Zurückgezogen |
| Local Institution - 0041 | Xi'an | Zurückgezogen | |
| Local Institution - 0045 | Xiamen | Fujian | Zurückgezogen |
| Local Institution - 0042 | Zhengzhou | Henan | Zurückgezogen |
France
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| ICO Papin | Angers | Maine-et-Loire | Rekrutiert |
| Chu Jean Minjoz | Besançon | Doubs | Rekrutiert |
| Hospices Civils de Lyon - Hopital Louis Pradel | Bron | Rhône | Rekrutiert |
| Centre Hospitalier Intercommunal de Créteil | Créteil | Rekrutiert | |
| L Hopital Nord Ouest | Gleizé | Rhône | Rekrutiert |
| Chu Grenoble Alpes | La Tronche | Isère | Rekrutiert |
| Assistance Publique Hôpitaux de Marseille - Hôpital Nord | Marseille | Rekrutiert | |
| Centre Hospitalier Universitaire de Nice - Hopital Pasteur | Nice | Alpes-Maritimes | Rekrutiert |
| Centre Antoine-Lacassagne | Nice | Alpes-Maritimes | Rekrutiert |
| Groupe hospitalier Paris saint Joseph | Paris | Île-de-France Region | Rekrutiert |
| CHU Bordeaux Haut-Leveque | Pessac | Aquitaine | Rekrutiert |
| Local Institution - 0051 | Poitiers | Vienne | Zurückgezogen |
| Centre Hospitalier de Cornouaille Quimper - Concarneau | Quimper | Rekrutiert | |
| Institut de Cancérologie de l'Ouest | Saint-Herblain | Loire-Atlantique | Rekrutiert |
| Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes | Saint-Herblain | Loire-Atlantique | Rekrutiert |
| Hôpital d'Instruction des Armées Bégin | Saint-Mandé | Rekrutiert | |
| Nouvel Hôpital Civil (NHC) | Strasbourg | Alsace | Rekrutiert |
| Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau | Tours | Rekrutiert |
Germany
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Klinikum Neuperlach | München | Rekrutiert |
Greece
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Alexandra General Hospital of Athens | Athens | Attikí | Rekrutiert |
| Metropolitan Hospital | Attiki | Rekrutiert | |
| Theagenio Hospital | Thessaloniki | Kentrikí Makedonía | Rekrutiert |
Hungary
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Orszagos Koranyi Pulmonologiai Intezet | Budapest | Rekrutiert | |
| Orszagos Onkologiai Intezet | Budapest | Rekrutiert |
Israel
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Bnai Zion Medical Center | Haifa | Rekrutiert | |
| Shaare Zedek Medical Center | Jerusalem | Jerusalem | Rekrutiert |
| Tel Aviv Sourasky Medical Center - Oncology - Hematology/Oncology | Tel Aviv | Rekrutiert |
Italy
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola | Bologna | Rekrutiert | |
| Azienda Ospedaliera Universitaria Careggi | Florence | Tuscany | Rekrutiert |
| IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" | Meldola | Emilia-Romagna | Rekrutiert |
| Istituto Europeo di Oncologia IRCCS | Milan | Rekrutiert | |
| Istituto Europeo di Oncologia IRCCS | Milan | Rekrutiert |
51 weitere Studienzentren sind im Registereintrag aufgeführt.
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 27. Oktober 2026
Studienzentrum entfernt
1 site removed (101 total)
102101
- 9. Oktober 2026
Studienzentrum hinzugefügt
2 sites added (102 total)
100102
- 18. August 2026
Studienzentrum entfernt
1 site removed (100 total)
101100
- 27. Juli 2026
Studienzentrum hinzugefügt
1 site added (101 total)
100101